GlassScriptPhysician profile
Ayman H Basali
NPI 1861457509
$4,942.70
in general payments reported to CMS, 2019-2025
36 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $900 · 2020: $269 · 2021: $1,408 · 2022: $521 · 2023: $360 · 2024: $955 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,845.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $1,010.99 | 2019-2025 | Xtampza, Belbuca |
| Genesys Orthopedics Systems, L.L.C. | $802.72 | 2021 | |
| Abbott Laboratories | $447.69 | 2019-2025 | Eterna, Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $290.27 | 2021-2025 | Relistor |
| Amgen INC. | $251.81 | 2019-2024 | Krystexxa |
| Medtronic, INC. | $247.27 | 2023-2024 | Intellis Adaptivestim |
| Scilex Pharmaceuticals INC. | $237.12 | 2019-2022 | |
| Biodelivery Sciences International, INC. | $232.05 | 2019-2021 | |
| Forte Bio-Pharma LLC | $182.02 | 2024 | Prolate, Nalocet |
| Flowonix Medical Incorporated | $136.95 | 2019 | |
| Nevro Corp. | $119.90 | 2019-2024 | Senza |
| Averitas Pharma INC. | $118.95 | 2024-2025 | Qutenza |
| Stimwave Technologies Incorporated | $114.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $112.85 | 2019-2021 | |
| Daiichi Sankyo INC. | $92.17 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $74.62 | 2022 | |
| Boston Scientific Corporation | $54.83 | 2024-2025 | General - Pain Management |
| Vertex Pharmaceuticals Incorporated | $39.55 | 2024-2025 | |
| Abbvie INC. | $39.16 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $37.97 | 2022-2023 | Seglentis |
| Horizon Therapeutics Plc | $34.36 | 2019-2020 | |
| Globus Medical, INC. | $30.20 | 2025 | Senza |
| Almatica Pharma LLC | $30.10 | 2021 | |
| Impel Pharmaceuticals LLC | $19.93 | 2025 | Trudhesa |
| Medtronic USA, INC. | $19.83 | 2020 | |
| Nalu Medical, INC. | $19.71 | 2024 | Nalu Neurostimulation System |
| Foundation Fusion Solutions, LLC | $17.56 | 2024 | |
| Saluda Medical Americas, INC. | $16.19 | 2024 | Evoke |
| Zyla Life Sciences, INC. | $15.99 | 2019 | |
| Si-Bone, INC. | $15.93 | 2021 | |
| Stryker Corporation | $14.99 | 2024 | Spinejack |
| Pfizer INC. | $13.91 | 2019 | |
| Painteq LLC | $13.55 | 2024 | Painteq |
| Lilly USA, LLC | $13.40 | 2019 | |
| Assertio Therapeutics, INC. | $11.81 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayman Basali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.